摘要
目的探讨异甘草酸镁联合恩替卡韦对慢性乙型肝炎HBeAg阳性患者治疗指标的影响,从中寻找现阶段更理想的治疗方案。方法将2013年1月-2014年6月在无锡市第五人民医院肝病科住院或门诊治疗的慢性乙型肝炎HBeAg阳性患者96例,随机分为两组,其中治疗组51例患者给予异甘草酸镁200mg静脉滴注,每日1次,采用较长疗程逐步减少用药次数的方法给药,疗程16周,同时给以恩替卡韦片0.5mg空腹口服,每日1次,疗程亦为16周;对照组45例患者给予恩替卡韦片0.5mg空腹口服,每日1次,疗程16周。结果治疗组在治疗后HBV-DNA阴转率为90.2%,HBeAg阴转率为23.5%,HBeAg转换率为21.6%,均优于对照组的84.4%、20.0%和17.8%,差异有统计学意义(P<0.05);两组患者在治疗前后肝纤维化指标均有改善,但治疗后组间比较,治疗组肝纤维化指标改善优于对照组,差异有统计学意义(P<0.05)。结论异甘草酸镁联合恩替卡韦治疗慢性乙型肝炎HBeAg阳性患者能获得更高的HBV-DNA阴转率、HBeAg阴转率/HBeAg转换率以及能更好的改善肝纤维化程度,为现阶段更为理想治疗方案。
OBJECTIVE To investigate the clinical effect of treatment of magnesium isoglycyrrhizinate （MgIG） com‐bined with Entecavir on therapeutic indexes of patients with HBeAg‐positive chronic hepatitis B .METHODS Total‐ly 96 patients with HBeAg‐positive chronic hepatitis B were randomly divided into two groups .The treatment group （51 cases） was given magnesium isoglycyrrhizinate （200 mg/d） for intravenous infusion once a day and En‐tecavir （0 .5 mg/d） for 16 weeks in a long‐term gradually decreasing trend .The control group （45 cases） was treated with Entecavir （0 .5 mg/d） for oral administration once a day in fasting with the treatment course of 16 weeks .RESULTS The negative conversion rates of HBV‐DNA and HBeAg and the HBeAg conversion rate were 90 .2% ,23 .5% and 21 .6% in the treatment group ,superior to 84 .4% ,20 .0% and 17 .8% in the control group and the difference was significant （P〈0 .05） .The liver fibrosis indicators of two groups were both improved ,but the treatment group got much more improvement after treatment ,the difference was significant （P〈 0 .05） . CONCLUSION Magnesium isoglycyrrhizinate combined with Entecavir for HBeAg‐positive chronic hepatitis B has a good clinical efficacy ,which can achieve higher negative conversion rates of HBV‐DNA and HBeAg and HBeAg conversion rate and can improve liver fibrosis ,which is a more promising regimen at present .
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2015年第20期4688-4690,共3页
Chinese Journal of Nosocomiology
基金
江苏省科技厅研究基金资助项目(JS0312111)
